T Matysiak-Budnik1, E Coron, J-F Mosnier, M Le Rhun, H Inoue, J-P Galmiche. 1. Institut des Maladies de l'Appareil Digestif - INSERM U913, CIC 04 et Service d'Hépato-Gastroentérologie, Hôtel Dieu, CHU de Nantes, 44093 Nantes, France. tamara.matysiakbudnik@chu-nantes.fr
Abstract
BACKGROUND AND AIMS: Celiac disease is a gluten-induced enteropathy whose diagnosis is based on histological evidence of villous atrophy. The diagnosis may be difficult if the orientation of histological sections is other than optimal. During upper gastrointestinal endoscopy we studied in vivo duodenal mucosa in patients with celiac disease using endocytoscopy, a novel diagnostic technique allowing in vivo real-time visualization of mucosa under x 450 magnification. METHODS: Sixteen patients with documented celiac disease and seven controls without celiac disease were studied. Endocytoscopic images obtained from several fields were compared in a blinded fashion to standard histology. RESULTS: Endocytoscopy showed three different patterns of in vivo histology: (1) the presence of normal-appearing, long, thin villi, lined with clearly distinguishable surface epithelial cells, considered to be normal duodenal mucosa (n = 15, all controls and eight celiac disease patients); (2) the presence of thick, shortened villi, reflecting partial villous atrophy (n = 4); and (3) the total absence of villi and the presence of enlarged crypt orifices, reflecting total villous atrophy (n = 4). Good concordance between endocytoscopy and standard histology was found in all 16 patients with celiac disease. CONCLUSIONS: Endocytoscopy allows in vivo, real-time, noninvasive visualization and characterization of villous architecture and may be a promising method for in vivo evaluation of duodenal mucosa in celiac disease. Georg Thieme Verlag KG Stuttgart. New York.
BACKGROUND AND AIMS: Celiac disease is a gluten-induced enteropathy whose diagnosis is based on histological evidence of villous atrophy. The diagnosis may be difficult if the orientation of histological sections is other than optimal. During upper gastrointestinal endoscopy we studied in vivo duodenal mucosa in patients with celiac disease using endocytoscopy, a novel diagnostic technique allowing in vivo real-time visualization of mucosa under x 450 magnification. METHODS: Sixteen patients with documented celiac disease and seven controls without celiac disease were studied. Endocytoscopic images obtained from several fields were compared in a blinded fashion to standard histology. RESULTS: Endocytoscopy showed three different patterns of in vivo histology: (1) the presence of normal-appearing, long, thin villi, lined with clearly distinguishable surface epithelial cells, considered to be normal duodenal mucosa (n = 15, all controls and eight celiac diseasepatients); (2) the presence of thick, shortened villi, reflecting partial villous atrophy (n = 4); and (3) the total absence of villi and the presence of enlarged crypt orifices, reflecting total villous atrophy (n = 4). Good concordance between endocytoscopy and standard histology was found in all 16 patients with celiac disease. CONCLUSIONS: Endocytoscopy allows in vivo, real-time, noninvasive visualization and characterization of villous architecture and may be a promising method for in vivo evaluation of duodenal mucosa in celiac disease. Georg Thieme Verlag KG Stuttgart. New York.
Authors: Ralf Kiesslich; Martin Goetz; Arthur Hoffman; Peter Robert Galle Journal: Nat Rev Gastroenterol Hepatol Date: 2011-09-06 Impact factor: 46.802
Authors: Alex J Thompson; Michael Hughes; Salzitsa Anastasova; Laurie S Conklin; Tudor Thomas; Cadman Leggett; William A Faubion; Thomas J Miller; Peter Delaney; François Lacombe; Sacha Loiseau; Alexander Meining; Rebecca Richards-Kortum; Guillermo J Tearney; Paul Kelly; Guang-Zhong Yang Journal: Nat Rev Gastroenterol Hepatol Date: 2017-11-15 Impact factor: 46.802
Authors: Heiko Pohl; Barbara T Tanczos; Birgit Rudolph; Alexander Meining; Ahmed C Khalifa; Thomas Rösch; Daniel C Baumgart Journal: Dig Dis Sci Date: 2011-09-08 Impact factor: 3.199